Freenome Signs an Agreement with ADC Therapeutics to Develop Biomarker for its ADCT-402 (loncastuximab tesirine)

Shots:

• ADC Therapeutics’s to utilize Freenome’s multiomics platform to identify biomarkers correlating with clinical response to ADC’s ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
• The focus of the collaboration is to develop innovative cancer therapies, highlighting the potential of Freenome’s platform providing tumor and immune signatures for hematological cancers in addition to solid tumors
• Freenome’s multiomics platform detects biological signals from a routine blood draw, integrating assays for cell-free DNA, methylation, and proteins and incorporates a multidimensional view of both tumor- and immune-derived signatures enabling the early detection of cancer

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: ADC Therapeutics